成纤维细胞生长因子受体
糖酵解
成纤维细胞生长因子
FGF21型
生物
细胞生物学
自噬
癌症研究
信号转导
化学
生物化学
受体
新陈代谢
细胞凋亡
作者
Yuanli Zhen,Kai Liu,Lei Shi,Simran Shah,Qin Xu,Haley Ellis,Eranga Roshan Balasooriya,Johannes Kreuzer,Robert Tyler Morris,Albert S. Baldwin,Dejan Juric,Wilhelm Haas,Nabeel M. Bardeesy
标识
DOI:10.1038/s41467-024-47514-y
摘要
Genomic alterations that activate Fibroblast Growth Factor Receptor 2 (FGFR2) are common in intrahepatic cholangiocarcinoma (ICC) and confer sensitivity to FGFR inhibition. However, the depth and duration of response is often limited. Here, we conduct integrative transcriptomics, metabolomics, and phosphoproteomics analysis of patient-derived models to define pathways downstream of oncogenic FGFR2 signaling that fuel ICC growth and to uncover compensatory mechanisms associated with pathway inhibition. We find that FGFR2-mediated activation of Nuclear factor-κB (NF-κB) maintains a highly glycolytic phenotype. Conversely, FGFR inhibition blocks glucose uptake and glycolysis while inciting adaptive changes, including switching fuel source utilization favoring fatty acid oxidation and increasing mitochondrial fusion and autophagy. Accordingly, FGFR inhibitor efficacy is potentiated by combined mitochondrial targeting, an effect enhanced in xenograft models by intermittent fasting. Thus, we show that oncogenic FGFR2 signaling drives NF-κB-dependent glycolysis in ICC and that metabolic reprogramming in response to FGFR inhibition confers new targetable vulnerabilities.
科研通智能强力驱动
Strongly Powered by AbleSci AI